Vincent Jean-Louis, Bassetti Matteo, François Bruno, Karam George, Chastre Jean, Torres Antoni, Roberts Jason A, Taccone Fabio S, Rello Jordi, Calandra Thierry, De Backer Daniel, Welte Tobias, Antonelli Massimo
Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, 1070, Brussels, Belgium.
Infectious Diseases Division, Santa Maria Misericordia University Hospital, 33100, Udine, Italy.
Crit Care. 2016 May 17;20(1):133. doi: 10.1186/s13054-016-1285-6.
Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains. In this review, we briefly discuss the importance of early infection diagnosis, before considering in more detail some of the key issues related to antibiotic management in these patients, including controversies surrounding use of combination or monotherapy, duration of therapy, and de-escalation. Antibiotic pharmacodynamics and pharmacokinetics, notably volumes of distribution and clearance, can be altered by critical illness and can influence dosing regimens. Dosing decisions in different subgroups of patients, e.g., the obese, are also covered. We also briefly consider ventilator-associated pneumonia and the role of inhaled antibiotics. Finally, we mention antibiotics that are currently being developed and show promise for the future.
重症患者经常发生感染,由于各种原因,包括诊断延迟、难以确定致病微生物以及抗生素耐药菌株的高流行率,对其进行管理具有挑战性。在本综述中,我们简要讨论早期感染诊断的重要性,然后更详细地考虑与这些患者抗生素管理相关的一些关键问题,包括联合治疗或单药治疗的争议、治疗持续时间以及降阶梯治疗。危重病可改变抗生素的药效学和药代动力学,特别是分布容积和清除率,并可影响给药方案。还涵盖了不同患者亚组(如肥胖患者)的给药决策。我们还简要考虑了呼吸机相关性肺炎以及吸入性抗生素的作用。最后,我们提到了目前正在研发且有望用于未来的抗生素。